Characterization of F3II, a sarcomatoid mammary carcinoma cell line originated from a clonal subpopulation of a mouse adenocarcinoma

Journal of Surgical Oncology

Volumn 62, Issue 4, 1996, Pages 288-297

  Alonso, Daniel F ^a   Farías, Eduardo F ^a   Urtreger, Alejandro ^a   Ladeda, Virginia ^a   Vidal, María Del Carmen C ^a   Bal De Kier Joffé, Elisa ^a  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

breast cancer; carcinosarcoma; heterogeneity; invasion; metastasis; urokinase

Indexed keywords

UROKINASE;

ADENOCARCINOMA; ANIMAL CELL; ARTICLE; BREAST CARCINOMA; BREAST CELL; CANCER GROWTH; CANCER INVASION; CELL SUBPOPULATION; CLONAL ANERGY; GENETIC HETEROGENEITY; GROWTH REGULATION; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; SARCOMA;

ADENOCARCINOMA; ANIMALS; CARCINOSARCOMA; CELL DIVISION; FEMALE; FIBRONECTINS; IMMUNOHISTOCHEMISTRY; MALE; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; TUMOR CELLS, CULTURED; URINARY PLASMINOGEN ACTIVATOR;

EID: 0029785179     PISSN: 00224790     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9098(199608)62:4<288::AID-JSO14>3.0.CO;2-1     Document Type: Article

References (34)

1. Hart IR, Fidler IJ: The implications of tumor heterogeneity for studies on the biology and therapy of cancer metastasis. Biochim Biophys Acta 651:37-50, 1981.
2. Dexter DL, Calabresi P: Intraneoplastic diversity. Biochim Biophys Acta 695:97-112, 1982.
3. Nowell PC: The clonal evolution of tumor cell populations. Science 194:23-28, 1976.
4. Fidler IJ, Kripke ML: Metastasis results from pre-existing variant cells within a malignant tumor. Science 197:893-895, 1977.
5. Mullins DE, Rohrlich ST: The role of proteinases in cellular invasiveness. Biochim Biophys Acta 695:177-214, 1983.
6. Danø K, Andreasen PA, Groøndahl-Hansen J, et al.: Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res 44:139-266, 1985.
7. Mignati P, Robbins E, Rifkin DB: Tumor invasion through the human amniotic membrane: requirement for a proteinase cascade. Cell 47:487-498, 1986.
8. Blasi F, Vassalli J-D, Danoø K: Urokinase-type plasminogen activator: proenzyme, receptors and inhibitors. J Cell Biol 104:801-804, 1987.
9. Møller LB: Structure and function of the urokinase receptor. Blood Coagul Fibrinol 4:293-303, 1993.
10. Van de Velde CJH, Van Putten LM, Zwavelling A: A new metastasizing mammary carcinoma model in mice. Model characteristics and applications. Eur J Cancer 13:555-565, 1977.
11. Fidler IJ: tumor heterogeneity and the biology of cancer invasion and metastasis. Cancer Res 38:2651-2660, 1978.
12. Dexter DL, Lee ES, Defusco DJ, et al.: Selection of metastatic variants from heterogeneous tumor cell lines using the chicken chorioallantoic membrane and nude mouse. Cancer Res 43:1733-1740, 1983.
13. Ostrowski LE, Ahsan A, Suthar BP, et al.: Selective inhibition of proteolytic enzymes in an in vivo mouse model for experimental metastasis. Cancer Res 46:4121-4128, 1986.
14. Jamasbi RJ, Perkins EH: Biological heterogeneity and radiation sensitivity of in vitro propagated lung metastatic lines originated from a transplatable squamous cell carcinoma of BALB/c mouse. In Vitro Cell Dev Biol 26:222-228, 1990.
15. Bal de Kier Joffé E, Puricelli L, Vidal MCC, Sacerdote de Lustig E: Characterization of two murine mammary adenocarcinoma tumors with different metastatic ability. J Exp Clin Cancer Res 2:151-160, 1983.
16. Alonso DF, Farías EF, Bal de Kier Joffé E: Urokinase-type plasminogen activator activity released by clonal tumor cell subpopulations isolated during the growth of a murine mammary adenocarcinoma. J Exp Clin Cancer Res 13:211-216, 1994.
17. Bal de Kier Joffé E, Fanas EF, Alonso DF: Enhancement of heterogeneity of urokinase-type plasminogen activator secretion in clones selected during the growth of M3 murine mammary adenocarcinoma. Proc Am Assoc Cancer Res 34:79, 1993.
18. Puricelli L, Colombo LL, Gomez DE, et al.: Characterization of a new murine tumor variant with different in vivo behavior selected by its adhesive properties. Tumori 76:345-349, 1990.
19. Pereyra-Alfonso S, Haedo A, Bal de Kier Joffé E: Correlation between urokinase-type plasminogen activator production and the metastasizing ability of two murine mammary adenocarcinomas. Int J Cancer 42:59-63, 1988.
20. Laemmli UK: Cleavage of structural proteins during assembly of the head of bacteriophage T4. Nature 227:680-685, 1970,
21. Granelli-Piperno A, Reich E: A study of proteases and protease-inhibitor complexes in biological fluids. J Exp Med 148:223-234, 1978.
22. Saksela O: Radial caseinolysis in agarose: a simple method for detection of plasminogen activator in the presence of inhibitory substances and serum. Anal Biochem 111:276-282, 1981.
23. Alonso DF, Farias EF, Bal de Kier Joffé E: Impairment of fibrinolysis during the growth of two murine mammary adenocarcinomas. Cancer Lett 70:181-187, 1993.
24. Jankum J, Maher VM, McCormick JJ: Malignant transformation of human fibroblast correlates with increased activity of receptor-bound plasminogen activator. Cancer Res 51:1221-1226, 1991.
25. Jasnis MA, Klein S, Monte M, et al.: Polyamines prevent DFMO-mediated inhibition of angiogenesis. Cancer Lett 79:39-43, 1994.
26. Lucero Gritti MF, García de Palazo IE, Meiss RP, Bonfil RD: Establishment and characterization of a new metastatic cell line (M3MC) derived from a murine mammary tumor. J Exp Clin Cancer Res 13:113-119, 1994.
27. Hart IR, Talmadge JE, Fidler IJ: Metastatic behavior of a murine reticulum cell sarcoma exhibiting organ-specific growth. Cancer Res 41:1281-1287, 1981.
28. Krompecher E: Der drusernartige Oberflachen-Epitheliak-rebscarcinoma epitheliae Adenoides. Beitr Pathol 28:1-41, 1900.
29. Wick MR, Swanson PE: Carcinosarcomas: current perspectives and an historical review of nosological concepts. Semin Diag Pathol 10:118-127, 1993.
30. Ehrlich P, Apolant H: Zur Kenntnis der Sarcomentwicklung bei Carcinomtransplantationen. Zentralbl Allg Pathol 17:513-553, 1906.
31. Foschini MP, Dina RE, Eusebi V: Sarcomatoid neoplasms of the breast: proposed definitions for biphasic and monophasic sarcomatoid mammary carcinomas. Semin Diag Pathol 10:128-136, 1993.
32. Sahin AA, Sneige N: Pathologic assessment of prognostic factors in patients with operable breast cancer. Cancer Bull 45:495-499, 1993.
33. Nowell PC: Mechanisms of tumor progression. Cancer Res 46:2203-2207, 1986.
34. Nicolson GR: Cancer progression and growth: relationship of paracrine and autocrine growth mechanisms to organ perference of metastasis. Exp Cell Res 204:171-180, 1993.